GlassScriptPhysician profile
Belal Kaseer
NPI 1518461755
$6,603.41
in general payments reported to CMS, 2019-2025
19 companies · $1,088 in 2025
The $1,088 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $32.31 · 2021: $113 · 2022: $400 · 2023: $2,287 · 2024: $2,558 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Grant: $1,745 · Travel and Lodging: $1,264 · Education: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.67 |
| Grant | $1,745.30 |
| Travel and Lodging | $1,263.62 |
| Education | $462.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,563.55 | 2022-2025 | Cardiomems, Ensite, Optis |
| Boston Scientific Corporation | $2,226.58 | 2024-2025 | Avvigo Guidance System, Synergy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $338.95 | 2022-2025 | Lifevest |
| Shockwave Medical, INC | $231.03 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $188.29 | 2023-2024 | Wainua, Brilinta, Farxiga |
| Abiomed | $142.57 | 2025 | |
| Janssen Pharmaceuticals, INC | $133.44 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $127.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $122.84 | 2024-2025 | |
| Esperion Therapeutics, INC. | $112.91 | 2021 | |
| Stryker Corporation | $101.58 | 2025 | Flowtriever |
| Amgen INC. | $86.16 | 2022 | |
| Teleflex LLC | $71.01 | 2023-2024 | Manta, Supercross |
| Spectrawave, INC | $31.08 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.77 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $30.06 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $24.48 | 2024 | Arcalyst |
| Cvrx, INC. | $22.59 | 2025 | Barostim Neo System |
| Heartflow, INC. | $18.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belal Kaseer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.